Cristina Sastre
Av. Reyes Católicos 2
Madrid, MD 28040, Spain
Madrid, MD 28040, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice.
Journal: Scientific reports
Published: September 23, 2016
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 23, 2015
Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
Journal: Atherosclerosis
Published: November 20, 2014
Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice.
Journal: Journal of the American Heart Association
Published: August 06, 2014
Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice
Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Published: March 27, 2014
Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.
Journal: Journal of cellular and molecular medicine
Published: July 04, 2013
HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: January 05, 2013
Targeting chemokines in proteinuria-induced renal disease.
Journal: Expert opinion on therapeutic targets
Published: July 17, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026